Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Clinical trial NCT03599453 · COMPLETED

Trial details

NCT number: NCT03599453
Sponsor: Roswell Park Cancer Institute
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Triple -Negative Breast Cancer Estrogen Receptor Negative HER2/Neu Negative Anatomic Stage IV Breast Cancer AJCC Progesterone Receptor Negative

Start date: 2019-01-09
Primary completion: 2020-09-02
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.